Herb-separated moxibustion on navel combined with / 中国针灸

OBJECTIVE@#To compare the clinical therapeutic effect between herb-separated moxibustion on navel combined with @*METHODS@#A total of 66 patients with non-liquefaction semen of dampness and heat diffusing downward were randomized into an observation group (33 cases, 2 cases dropped off) and a control group (33 cases, 2 cases dropped off). In the control group, @*RESULTS@#After treatment, the time of semen liquefaction was shortened (@*CONCLUSION@#Herb-separated moxibustion on navel combined with

A clinical study on effectiveness of Ningmitai Capsule combined with Dirithromycin Enteric Tablets in treatment of semen nonliquefaction with positive Ureaplasma urealyticum / 中草药

Objective To investigate the clinical effect of Ningmitai Capsule combined with Dirithromycin Enteric Tablets in the treatment of positive semen nonliquefaction in the culture of Ureaplasma urealyticum (Uu). Methods A total of 120 cases of semen liquefaction patients with positive semen Uu culture were randomly divided into treatment group with 80 cases and control group with 40 cases, which were continuous administrated for two weeks for a period of treatment and observated for two courses of treatment. In the treatment group, four Ningmitai Capsules were taken orally per time, three times per day, and 0.5 g Dirithromycin Enteric Tablets were taken orally per time, once per day, after meals, while the control group only took the Dirithromycin Enteric Tablets orally. Uu negative conversion rate and semen liquefaction time (min) were observed, and adverse reactions were also observed. Results The Uu negative conversion rate in the treatment group and control group after 2 weeks, 4 weeks was 72.5%, 95.0% and 55%, 92.5%, respectively, the negative conversion rate of treatment group was obviously higher than that of control group after 2 weeks treatment (P 0.05). The semen liquefaction time before treatment in the treatment group and control group respectively was (76.19 ± 14.13) min and (77.08 ± 13.34) min, which was (58.64 ± 13.15) min and (67.12 ± 12.52) min two weeks after treatment, (48.64 ± 12.38) min and (56.12 ± 12.86) min 4 weeks after treatment were, semen liquefaction time of the two groups before and after treatment was significant different (P < 0.05), and the treatment group was better than control group (P < 0.01). Conclusion Ningmitai Capsule combined with Dirithromycin Enteric Tablets can partly shorten the Uu negative conversion time, obviously shorten the semen liquefaction time, and has obvious clinical efficacy for Uu positive semen nonliquefaction disease.

Efficacy and safety of Ningmitai Capsule in treatment towards type III prostatitis: A randomized, double-blind, placebo-control clinical trial / 中草药

Objective: To evaluate the efficacy and safety of Ningmitai Capsule in the treatment towards type III prostatitis. Methods A randomized, double-blind, placebo-control clinical trial was conducted. A total of 50 patients diagnosed as type III prostatitis were divided into two groups with the ratio of 1:1. Patients of the trial group were treated with Ningmitai Capsule at the dose of four grain tid for 4 weeks, and patients of the control group were given placebo in the same way. The efficacy was evaluated by the NIH chronic prostatitis symptom index (NIH-CPSI) while safety-evaluation was evaluated by adverse events, results of urine routine examinations and hepatorenal-function tests. Results:After 4-week treatment, NIH-CPSI total scores were 23.96 ± 1.30 before treatment, and reduced to 16.04 ± 1.66 (P < 0.001). To the contrary, for all these scores, no significant statistical differences exist in placebo-control group. Pain-symptom scores, micturition-symptom scores and QOL scores were all statistically reduced in the trial group. No significant adverse events occurred in all patients who completed the study. Conclusion:Ningmitai Capsule is effective and safe in the treatment of type III prostatitis.

Ningmitai Capsule for the treatment of andrological diseases: Advances in studies / 中华男科学杂志

Ningmitai Capsule is a classical patent medicine prepared from multiple effective ingredients of Chinese herbal medicine, with a wide range of biological activities and a significant efficacy in the treatment of urogenital diseases. Ningmitai Capsule has been widely applied in the management of urological and andrological diseases, with a particularly ideal effect on chronic prostatitis, since its first introduction nearly 20 years ago. With no obvious adverse effect on the male reproductive system, it has also been gaining a gradual application in the treatment of such diseases as urinary tract infections, diabetes, non-gonococcal urethritis, seminal vesiculitis, acute epididymitis, overactive bladder, hematuria, and semen non-liquefaction. However, the definite efficacy of Ningmitai Capsule needs to be further verified with more large-scale multi-centered randomized controlled trials, and its pharmacological mechanism remains to be further explored via more biomolecular experiments. The present article focuses on the recent advances in the application and studies of Ningmitai Capsule in the treatment of urological and andrological diseases.

Curative efficacy of Ningmitai capsules unite Tamsulosin hydrochloride sustained realeased capsules treatment of Ⅲ type B prostatitis and its effects on level of the prostate fluid of IL-10 , TNF-α, PGE-2 / 中国生化药物杂志

Objective To study the curative efficacy of Ningmitai capsule unite amsulosin hydrochloride sustained realeased capsules treatment ofⅢ type B prostatitis and its effects on level of the prostate fluid of interleukin-10(IL-10), tumor necrosis factor alpha, prostaglandin E2.Methods 104 patients withⅢtype B prostatitis who received therapy from December 2015 to October 2016 in our hospital were selected as research objects, according to the treatment were divided into observation group and control group , the observation group was treated with Ningmitai capsules unite Tamsulosin hydrochloride sustained realeased capsules while the control group was treated with Tamsulosin hydrochloride sustained realeased capsules.Comparison curative effect ,before and after the treatment of chronic inflammatory prostate integral index, maximum urinary flow rate, average urine flow rate;Analysis before and after treatment prostate fluid of interleukin-10, tumor necrosis factor alpha, prostaglandin E2 level and WBC count.Results After treatment, the observation group total effective rate was 90.4%, significantly higher than the control group (P<0.05);After treatment, the observation group in the prostatic fluid IL-10, the TNF-α, PGE-2, the WBC levels were significantly lower than the control group (P<0.05),and after the treatment,chronic inflammatory prostate integral index of observation group was obviously lower than the control group, the maximum urinary flow rate, average urine flow rate is significantly higher than the control group (P<0.05).Conclusion Ningmitai capsules unite amsulosin hydrochloride sustained realeased capsules treatment Ⅲ type B prostatitis has significantly clinical curative effect, can pass down the prostate fluid of IL-10, the TNF alpha, PGE-2 levels, relieve the clinical symptoms.

The clinical efficacy ofNingmitai capsule combined with tolterodine in the treatment of overactiver bladder after transurethral resection of the prostate / 国际中医中药杂志

Objective To observe the clinical efficacy of Ningmitai capsule combined with Tolterodine in the treatment of overactiver bladder after transurethral resection of the prostate(TURP).Methods 63 TURP patients with bladder disease (OAB) in our hospital from October 2012 to October 2012 were selected and randomly divided into a treatment group (n=32) and a control group (n=31). From the date of operation, the control group was treated with tolterodine 2 mg, 2 times a day, while the treatment group was additional treated with Ningmitai capsule 4mg, 3 times a day based on the control group. All patients stopped to take medicine 5 days after catheter removal. The pain frequency and duration of bladder spasm after TURP in catheterization period and the urine volume per time, the number of urgent incontinence, and the number of urgent micturition average day in automatic micturition period were scored by OABSS.Results The number of bladder spasm in the first postoperative day(3.5 ± 0.5vs.4.4 ± 0.8,t=2.650), the second day(1.5 ± 0.9vs.1.8 ± 0.2,t=2.350) and the third day (0.4 ± 1.6vs. 1.1 ± 1.8,t=2.210) of the treatment group were all less than the control group (P>0.05). The 24 h average frequency of urination after catheter removal (6.2 ± 1.3vs. 9.4 ± 1.8,t=2.710), the average number of nocturia (1.5 ± 0.4vs. 3.9 ± 1.0,t=2.580), the average number of 24h urinary urgency (1.1 ± 0.3vs. 3.2 ± 0.8,t=2.660), the average number of incontinence in 24 h (0.5 ± 0.2vs. 2.4 ± 0.6,t=2.700) and OABSS total score  (4.6 ± 1.2vs. 6.9 ± 2.1,t=2.470) of the treatment group were all better than the control group (P<0.05). Conclusion Ningmitai capsule combined with tolterodine in the treatment of overactiver bladder after TURP has significant clinical effect, helping patients recovery and improving quality of life.

Meta-analysis on Ningmitai Capsule combined with antibiotics therapy for chronic prostatitis / 中草药

To evaluate if Ningmitai Capsule combined with antibiotics therapy is safer and more effective than simple antibiotics therapy for chronic prostatitis, we firstly retrieved the China journal full-text database (CNKI), China's outstanding master's/doctoral dissertation database, Wan Fang database, VIP science and technology periodical database, MEDLINE, and EMBASE. Secondly, we selected research literatures from 2000 to 2013 on Ningmitai Capsule combined with antibiotics therapy for chronic prostatitis. Then, the data were filtered by Cochrane system evaluation method and conducted for Meta-analysis on the effectiveness, chronic prostatitis symptoms index (NIH-CPSI) and microscopy count of white blood cell in expressed prostatic secretion (EPS-WBC) via Stata 12.0 software. Finally, 11 articles including 2 079 samples were totally involved. The Meta-analysis results showed that compared with simple antibiotics treatment, Ningmitai Capsule combined with antibiotics therapy significantly increased the cure rate[OR=2.47, 95% CI (2.08, 2.93)] and lowered NIH-CPSI[WMD=-8.14, 95% CI (-9.39, -6.90)] as well as EPS-WBC[WMD=-6.14, 95% CI (-8.11, -4.17)]. So the study suggests that Ningmitai Capsule can significantly improve the cure rate and related indicators of simple antibiotics therapy for chronic prostatitis, which provides certain references for improving clinical treatment.

Clinical observation on efficacy of Ningmitai capsule for treatment of patients with diabetic urinary tract infection / 中国中西医结合急救杂志

ObjectiveTo explore the clinical efficacy of Ningmitai capsule for treatment of patients with diabetic urinary tract infection.Methods A total of 100 diabetes patients with urinary tract infection from Zunyi First People's Hospital in Guizhou Province and Longkou Family Planning Service Station in Shandong Province wereenrolled in the study and randomly divided into control and treatment groups after they were informed and gave consent. With basic therapy to lower blood glucose, 65 cases in the treatment group were treated with Ningmitai capsule(4 granules/time, every grain of 0.38 g), while another 35 cases of the control group were given Sanjin tablets (4 granules/time, every grain of 0.29 g), 3 times a dayfor 2 weeks in both groups. Before and after treatment, the clinical effect, blood routine, urine routine, blood glucose, negative conversion ratio of midstream urine bacteria culture and tradition Chinese medicine syndrome curative effect in both groups were observed.Results The total effective rate of treatment group was significantly higher than that of the control group〔88.52%(54/61) vs. 70.59%(24/34),P0.05). Compared with those before treatment, after treatment, the urinary RBC and WBC were decreased in treatment group, while in control group WBC was decreased but RBC increased, and in the comparisons of above indexes between the two groups there were statistical significant differences〔RBC(cell/μL): 1.99±0.59 vs. 9.11±3.76, WBC(cell/μL): 23.09±6.18 vs. 63.72±25.76, bothP0.05). Negative conversion ratio of midstream urine bacterial culture in treatment group was significantly higher than that in control group〔80%(4/5) vs. 0(0/2)〕. Syndromes of traditional Chinese medicine were ameliorated at different degrees after treatment in both groups. The effectiveness of treatment group on urinary urgency, yellowish turbid urine and swelling pain in lower abdomen were obviously more valid than that of control group〔urinary urgency: 90.0%(54/60) vs. 61.8%(21/34), yellowish turbid urine: 75.0%(39/52) vs. 47.6%(10/21), swelling pain in lower abdomen: 74.5%(35/47) vs. 70.6%(12/17),P0.05).ConclusionThe clinical efficacy of Ningmitai capsule is better than that of Sanjin tablet for treatment of patients with diabetic urinary tract infection, and no adverse reaction has been seen in clinical observation.

Clinical observation on Ningmitai Capsule for treatment of hemospermia caused by vesiculitis / 中草药

Objective: To investigate the effects of Ningmitai Capsule in the treatment of hemospermia caused by vesiculitis. Methods: A total of 105 cases of male patients with diagnosis of hemospermia caused by vesiculitis were randomly divided into Ningmitai Capsule treatment group and antibiotic treatment group. Both groups were respectively given Ningmitai Capsule and Levofloxacin Tablets for 4 weeks. Hemospermia changes and clinical symptom improvement were adopted as a curative effect judgment standard, and changes were observed before the treatment and 2 weeks after the treatment stopped. Results: The total effective rate in Ningmitai Capsule group was 77.0%, and the total effective rate in the antibiotics group was 61.4%. Conclusion: Ningmitai Capsule used for the treatment of hemospermia caused by vesiculitis has obtained satisfactory results, and it has the advantage of mild drug side effects, better tolerance, and good economical efficiency.